Peng Soon Ng1, Peter J Dyck1, Ruple S Laughlin1, Prabin Thapa1, Marcus V Pinto1, P James B Dyck2. 1. From the Department of Neurology (P.S.N.), National Neuroscience Institute, Singapore; Department of Neurology (P.S.N., P.J.D., R.S.L., M.V.P., P.J.B.D.), and Division of Biomedical Statistics and Informatics (P.T.), Mayo Clinic, Rochester, MN. 2. From the Department of Neurology (P.S.N.), National Neuroscience Institute, Singapore; Department of Neurology (P.S.N., P.J.D., R.S.L., M.V.P., P.J.B.D.), and Division of Biomedical Statistics and Informatics (P.T.), Mayo Clinic, Rochester, MN. dyck.pjames@mayo.edu.
Abstract
OBJECTIVE: To determine the previously unknown incidence of lumbosacral radiculoplexus neuropathy (LRPN) and its association with diabetes mellitus (DM). METHODS: LRPN defined by clinical and electrophysiologic criteria was identified among Olmsted County, Minnesota, residents during a 16-year period (2000-2015) using the unique facilities of the Rochester Epidemiology Project. DM was ascertained using American Diabetes Association criteria. RESULTS: Of 1,892 medical records reviewed, 59 patients (33 men, 26 women) were identified as having LRPN. The median age was 70 years (range 24-88 years) and the median time of onset of symptoms to diagnosis was 2 months (range 1-72 months). DM was more frequent in patients with LRPN than in controls (39/59 vs 35/177, p < 0.001) but not in those with pre-DM (10/20 vs 55/142, p = 0.336). LRPN recurred in 3 patients with DM resulting in 62 LRPN episodes during the study period. The overall incidence of LRPN was 4.16/100,000/y (95% confidence interval [CI] 3.13-5.18). The incidences of LRPN among DM and non-DM groups were 2.79/100,000/y (95% CI 1.94-3.64) and 1.27/100,000/y (95% CI 0.71-1.83), respectively. The odds of LRPN among patients with DM and pre-DM was 7.91 (95% CI 4.11-15.21) and 1.006 (95% CI 1.004-1.012), respectively. CONCLUSIONS: LRPN incidence in Olmsted County of 4.16/100,000/y makes LRPN a common inflammatory neuropathy and is higher than that of other immune-mediated neuropathies (acute or chronic inflammatory demyelinating polyradiculoneuropathy, brachial plexus neuropathy) assessed within the same population. DM is a major risk factor for LRPN and thus justifies the continued classification of LRPN into diabetic and nondiabetic forms.
OBJECTIVE: To determine the previously unknown incidence of lumbosacral radiculoplexus neuropathy (LRPN) and its association with diabetes mellitus (DM). METHODS: LRPN defined by clinical and electrophysiologic criteria was identified among Olmsted County, Minnesota, residents during a 16-year period (2000-2015) using the unique facilities of the Rochester Epidemiology Project. DM was ascertained using American Diabetes Association criteria. RESULTS: Of 1,892 medical records reviewed, 59 patients (33 men, 26 women) were identified as having LRPN. The median age was 70 years (range 24-88 years) and the median time of onset of symptoms to diagnosis was 2 months (range 1-72 months). DM was more frequent in patients with LRPN than in controls (39/59 vs 35/177, p < 0.001) but not in those with pre-DM (10/20 vs 55/142, p = 0.336). LRPN recurred in 3 patients with DM resulting in 62 LRPN episodes during the study period. The overall incidence of LRPN was 4.16/100,000/y (95% confidence interval [CI] 3.13-5.18). The incidences of LRPN among DM and non-DM groups were 2.79/100,000/y (95% CI 1.94-3.64) and 1.27/100,000/y (95% CI 0.71-1.83), respectively. The odds of LRPN among patients with DM and pre-DM was 7.91 (95% CI 4.11-15.21) and 1.006 (95% CI 1.004-1.012), respectively. CONCLUSIONS: LRPN incidence in Olmsted County of 4.16/100,000/y makes LRPN a common inflammatory neuropathy and is higher than that of other immune-mediated neuropathies (acute or chronic inflammatory demyelinating polyradiculoneuropathy, brachial plexus neuropathy) assessed within the same population. DM is a major risk factor for LRPN and thus justifies the continued classification of LRPN into diabetic and nondiabetic forms.
Authors: Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: A Othman; M F Rütti; D Ernst; C H Saely; P Rein; H Drexel; C Porretta-Serapiglia; G Lauria; R Bianchi; A von Eckardstein; T Hornemann Journal: Diabetologia Date: 2011-11-29 Impact factor: 10.122
Authors: Rami Massie; Michelle L Mauermann; Nathan P Staff; Kimberly K Amrami; Jayawant N Mandrekar; Peter J Dyck; Christopher J Klein; P James B Dyck Journal: Brain Date: 2012-10 Impact factor: 13.501
Authors: Rohana J Wright; David E Newby; David Stirling; Christopher A Ludlam; Ian A Macdonald; Brian M Frier Journal: Diabetes Care Date: 2010-07 Impact factor: 17.152
Authors: Marcus V Pinto; Peng-Soon Ng; Ruple S Laughlin; Prabin Thapa; Catarina Aragon Pinto; Shahar Shelly; Kamal Shouman; Peter J Dyck; P James B Dyck Journal: Muscle Nerve Date: 2022-01-22 Impact factor: 3.852
Authors: Marcus V Pinto; Peng-Soon Ng; Benjamin M Howe; Ruple S Laughlin; Prabin Thapa; Peter J Dyck; P James B Dyck Journal: Neurology Date: 2021-03-02 Impact factor: 11.800
Authors: Antje Bischof; Veronika K Jaeger; Robert D M Hadden; Raashid A Luqmani; Anne-Katrin Pröbstel; Peter A Merkel; Ravi Suppiah; Anthea Craven; Michael P Collins; Thomas Daikeler Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-09-20